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Narrative reviewCardiac involvement in patients with cirrhosis: a focus on
clinical features and diagnosis
Anna Licataa, Giuseppina Novoc, Daniela Colombab, Antonino Tuttolomondob,
Massimo Galiad and Calogero Camma’aCirrhotic heart has been traditionally considered protected
from cardiovascular disease, even if a large amount of
literature has recently shown that patients affected by
chronic liver disease are exposed to cardiovascular events,
as well. Since the first recognition of cardiac involvement in
cirrhosis, all published studies explain that decompensated
cirrhotic patients suffer from haemodynamic changes,
currently known as hyperdynamic syndrome, which finally
lead to cirrhotic cardiomyopathy. This is defined by the
presence of a subclinical systolic dysfunction unmasked
under stress conditions, impaired diastolic function and
electrophysiological abnormalities, in the absence of any
known cardiac disease. In this review, we will discuss the
clinical and diagnostic features of this condition, the
prevalence of associated comorbidities, echocardiographic,opyright © 2015 Wolters Kluwer Health, Inc. Una
1558-2027 Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.electrocardiographic and cardiac magnetic resonance
hallmarks and the possible diagnostic role of serum
biomarkers.
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Along with haemodymanic changes usual of cirrhosis,
vasodilatation is the vascular modification finally leading
to multiorgan involvement, including the heart.1 In fact,
splanchnic vasodilatation is the first pathophysiological
stage of clinical complications of cirrhosis, while portal
hypertension and its sequelae (oesophageal or gastric
varices, ascites, spontaneous bacterial peritonitis) are
causes of admission to the hospital, worsening of clinical
conditions and death.2 Some other complications, invol-
ving more organs and systems, such as hepatic encepha-
lopathy, hepato-renal syndrome and pulmonary
involvement, which represent widespread functional
consequences of hyperdynamic syndrome, have been
deeply examined in a comprehensive review,2,3 and thus
will not be debated here, also considering that specific
guidelines have been already developed for their diag-
nosis and management.4 Cardiovascular dysfunction in
cirrhotic patients has been revealed since 1953, when
Kowalsky and Abelmann5 described an impaired contrac-
tility function in patients with alcoholic cirrhosis. How-
ever, about 50 years later, the cardiac involvement of
cirrhosis has been characterized and defined as cirrhotic
cardiomyopathy.6 Commonly, cardiac dysfunction devel-
ops as a subclinical condition, being evident only in
certain situations or during stressing procedures, such
as large volume paracentesis, transjugular intrahepatic
portal shunt (TIPS) insertion and liver transplantation.
Recently, different cohort studies have shown a highincidence of cardiovascular mortality and morbidity in
cirrhotic patients,7–9 and moreover, a high prevalence of
asymptomatic coronary artery disease (CAD) has been
displayed by cirrhotic patient candidates for transplan-
tation.10 Therefore, in this review, we aimed to clearly
define the clinical features and diagnosis of cardiovascu-
lar dysfunction occurring in cirrhotic patients, the preva-
lence of associated comorbidities, echocardiographic,
electrocardiographic and cardiac magnetic resonance
hallmarks and the possible diagnostic role of serum
biomarkers.
Cirrhotic cardiomyopathy
Patients with advanced cirrhosis are characterized by a
hyperdynamic circulatory state, revealed by raised car-
diac output (CO), heart rate (HR) and blood volume,
reduced systemic vascular resistance and low, normal or
decreased blood arterial pressure.1,5,11 The hyperdy-
namic syndrome defined above is responsible of the
cardiovascular complications finally leading to cirrhotic
cardiomyopathy. Prevalence of cirrhotic cardiomyopathy
is unknown, because diagnosis is difficult and cardiac
function at rest is usually normal. Most patients are
diagnosed during the ascitic phase of the liver disease;
when following the splanchnic vasodilation and low vas-
cular resistance, the CO is increased. Patients remain
asymptomatic for a long time (many years), because
the arterial vasodilation due to reduced vascular periph-
eral resistances determines afterload reduction, maskinguthorized reproduction of this article is prohibited.
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increased and it cannot further improve during stress
conditions. Therefore, during stressing procedures that
acutely increase the cardiac preload, cirrhotic heart is
unable to improve systolic function and cardiac failure
becomes evident. Worsening of cardiac function after
liver transplantation, however, resolves briefly within 6
months, and hyperdynamic circulation disappears.6,12
Until now, there are no standardized criteria for the
diagnosis of cirrhotic cardiomyopathy. It should be sus-
pected in patients with end-stage liver disease, and the
clinical suspicion can be confirmed by physical stress
(physical exercise) or pharmacological test (dobutamine
stress echocardiography). Echocardiography is a useful
diagnostic tool to detect diastolic dysfunction and sub-
clinical impairment of systolic function. Common diag-
nostic features are also electrophysiological abnormalities
such as long QT, usually revealed at 12-lead ECG.
Finally, cardiovascular magnetic nuclear resonance
(CMNR) is a promising method to screen cirrhotic
patients at risk of developing congestive heart failure,
in addition to the use of cardiac serum biomarkers.
Pathogenesis
It has been hypothesized that several mechanisms may
be responsible for the specific cardiac dysfunction
observed in cirrhosis: autonomic dysfunction, nitric
oxide, carbon monoxide and endocannabinoids. In
patients with cirrhosis, a reduced response to beta-adre-
nergic stimulation and consequently a blunted inotropic
and chronotropic response has been clearly documented.
In fact, HR does not properly increase under stimulation
(stress, drugs and so on) and the baroreflex function is
altered, with a tendency to orthostatic hypotension.12 A
possible explanation could be the downregulation of the
b-adrenergic receptors secondary to long-term exposure
to increased circulating catecholamine levels.13 Another
explanation could be the impaired cell membrane fluid-
ity, observed in cirrhotic patients, which could interfere
with a correct function of receptors and signal transduc-
tion pathway.14 The production of nitric oxide is
increased in cirrhotic patients, probably due to elevated
level of proinflammatory cytokine and gut-derived bac-
terial endotoxins. This is a potent vasodilator and plays a
key role in the peripheral vasodilation and hyperdynamic
state proper of cirrhosis.15,16Moreover, nitric oxide is able
to reduce cardiac contractility, inhibiting the b-adrener-
gic stimulation of cAMP and activating the guanylate–
cyclase mediated cGMP production, which is able to
block the extracellular calcium influx.12,17 Carbon mon-
oxide, a degradation product of heme, also has a role in
cardiac dysfunction, in cirrhosis, via activation of guany-
late–cyclase and production of cGMP.18,19 Production of
endogenous cannabinoids (such as anandamide) is
increased in experimental models of cirrhotic rats, prob-
ably as a result of bacterial endotoxins.20,21 Endogenous
cannabinoids are involved in vasodilation, induction ofpyright © 2015 Wolters Kluwer Health, Inc. Unauportal hypertension and reduction of cardiac contraction.
Endocannabinoids may induce systemic vasodilation
probably activating the G-protein coupled inhibitory
receptors (CB1 and CB2) in the vascular endo-
thelium.22,23 Moreover, they can impair microcirculation
of the liver and favour the development of portal hyper-
tension and hyperdynamic circulation through the induc-
tion of apoptosis in hepatic stellate cells.24 Finally, the
negative inotropic effect on cardiac contractility could be
related to interference with the G-protein coupled inhib-
itory receptors CB1.25 Figure 1 summarizes mechanisms
of cardiovascular dysfunction in cirrhosis.
Associated comorbidities in cirrhotic patients
For many years, it has been believed that cirrhotic
patients could be protected against cardiovascular dis-
ease, thanks to haemostatic defects, such as coagulation
impairment and low platelet count, low cholesterol levels
and low blood pressure. However, two recent published
cohort studies carried out in cirrhotic patients undergoing
evaluation for liver transplantation reported a high preva-
lence of asymptomatic CAD and coronary artery calcifi-
cation.26,27 Moreover, traditional risk factors have
become common in patients suffering from cirrhosis
because of increased survival rates and this probably
might explain the reported prevalence of CAD in this
clinical setting. Actually, age, male sex, dyslipidemia,
smoking habits and diabetes are independent risk factors
for CAD in cirrhotic patients candidates for liver trans-
plant.28 In a large retrospective study of 1183 individuals
with cirrhosis of different causes, without any history of
chest pain or CAD, who underwent computerized angio-
graphy as part of a preliver transplant cardiac work-up, the
prevalence of silent CAD was around 8%, and conven-
tional risk factors were reported as follows: 33.5% hyper-
tension, 24.2% diabetes and 1.1% hyperlipidemia; BMI
and cholesterol levels are usually lower in patients with
cirrhosis than in those without.10
However, it is not easy to understand the amount of
cardiac dysfunction really attributable to haemodynamic
changes of cirrhosis and that induced by coexisting and
interfering conditions. In fact, chronic liver disease
patients usually present some condition, such as smoking,
hypertension or diabetes, and it is well known that all the
above-mentioned disorders represent cardiovascular risk
factors. Nevertheless, the cause of chronic liver disease
per se could be the cause of cardiomyopathy (e.g. alcohol),
and accordingly, heavy drinkers may suffer from heart
failure before a significant liver damage has occurred. In
this regard, in the study by An et al.,10 subgroup analysis
showed that alcoholic cirrhosis was an independent risk
factor, unlike hepatitis virus related disease. Therefore,
the real impact of cardiovascular risk in cirrhosis is still
undefined; at this time, no specific guidelines have been
developed in this clinical setting and physicians follow
the general rules for the preoperative assessment ofthorized reproduction of this article is prohibited.
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identify novel and accurate scores to evaluate cirrhotic
patients, with cardiovascular risk factors or presence
of CAD.
Another question considers the hepatitis C virus (HCV)-
related cirrhosis. It has been shown that there are differ-
ent potential mechanisms linking HCV infection to car-
diovascular alteration. The question raised is whether the
HCV per se or through induction of metabolic disorders
such as insulin resistance, liver steatosis and diabetes30
and/or inflammatory conditions [releasing of toxic free
fatty acids and proinflammatory cytokines, such as
tumour necrosis factor-a (TNF-a) and interleukin (IL)-
6] could be associated with increased cardiovascular
risk.31 In fact, the HCV chronically infected patients,
although they are usually characterized by a favourable
lipoprotein profile (reduced levels of very low density
lipoprotein and very low density lipoprotein cholesterol),
show a higher prevalence of carotid atherosclerosis.32 In
addition to the conventional cardiovascular risks factors,
other metabolic alterations can contribute to the highopyright © 2015 Wolters Kluwer Health, Inc. Unacardiovascular mortality in this clinical setting: vitamin D
deficiency and high industrial fructose consumption.33–35
Therefore, according to a recently published review,
HCV is able to directly and indirectly interfere with
glucose and lipid metabolism, resulting in a high preva-
lence of insulin resistance, hyperglycaemia and diabetes;
these factors, together with genetic background and
lifestyle, work synergically in increasing cardiovascular
risk of HCV-infected patients.36
Atherosclerotic plaque is the final step of inflammatory
process, whose initial phases are expressed by ‘endothelial
dysfunction’, which is considered one of the earliest steps of
atherogenesis. Several studies suggested that non inflam-
matory liver disease (NAFLD), the common cause of liver
disease in Western countries, could be considered the
hepatic manifestation of metabolic syndrome.37 Metabolic
syndrome represents a condition notoriously associated
with atherosclerosis and some authors reported a precise
relationship between NAFLD and cardiovascular risk
especially among patients with metabolic syndrome.38 In
a recent review, Ciccone et al.39 stressed the link betweenuthorized reproduction of this article is prohibited.
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common inflammatory nature of both diseases. Particularly,
NAFLD is associated with increased CAD prevalence40,41
and a worse prognosis.42 Furthermore, the likelihood of
coronary multivessel involvement is higher in patients with
NAFLD than in controls and the Gensini score is higher in
patients with NAFLD.43 Finally, it could be interesting to
exclude the presence of anatomical variation in internal
carotid artery (i.e. dolichocarotid) linked to aging or chronic
disease such as atherosclerosis and hypertension44 and
potential causes of cerebrovascular or cardiovascular events.
However, literature data suggest that NAFLD is linked to
cardiovascular risk independently of metabolic syndrome,
and therefore, NAFLD is involved in the pathogenesis of
cardiovascular disease.45–47 Patient’s comorbidity burden
has been recently quantified in a single number by a
comorbidity score system, the Cir-Com score.48 It is
considered simpler than the Charlson Index, because it
takes into account only nine items. Thus, as comorbidities
(diabetes, cardiovascular disease, lung or kidney disease,
smoking and so on) are common in these patients, a better
understanding of interaction between a single comorbidity
and cirrhosis will improve our knowledge.
Echocardiographic characteristics
Systolic function in the majority of cirrhotic patients has
been traditionally considered normal at rest. Left ven-
tricular ejection fraction (LVEF), measured by conven-
tional two-dimensional (2D) echocardiography, is the
most common method for quantifying left ventricular
function. However, this method is not sensitive enough
to detect latent myocardial dysfunction. Moreover, in the
presence of volume overload, LVEF does not reliably
express contractility.
Pulsed Doppler analysis can help to identify subtle
systolic alteration, even at rest. In fact, in cirrhotic
patients, preejection period (PEP) is decreased and left
ventricular ejection time (LVET) is prolonged; con-
sequently, the ratio between PEP and LVET is
decreased. In this way, the duration of mechanical systole
remains constant, but left ventricular ejection period
takes a larger percentage of the time interval. This
observation suggests, in patients with chronic liver dis-
ease,49 the existence of an abnormal electromechanical
coupling rather than a true ventricular mechanical fail-
ure.50 In addition, reduction of peripheral resistance and,
thus decrease of arterial elastance, in cirrhotic patients
involves an abnormal ventricular arterial coupling and
reduced cardiac efficiency.
Tissue Doppler echocardiography enables the assess-
ment of the deformation of longitudinal fibres revealing
early alterations of myocardial function in cirrhosis even
in the absence of a significant overload for the heart.
Kazankov et al.51 found, compared with healthy controls,
reduced S wave value at Tissue Doppler analysis inpyright © 2015 Wolters Kluwer Health, Inc. Unaucirrhotic patients that is suggestive of reduced systolic
longitudinal function (see Fig. 2).
Speckle tracking echocardiography, which objectively
measures intrinsic deformation of myocardial fibres, is
not influenced by volume load condition and is more
sensitive and accurate to detect subtle systolic dysfunc-
tion. Peak systolic longitudinal strain is reduced at rest, in
cirrhotic patients compared with controls with similar
ejection fraction. Conversely, circumferential shortening,
during the ventricular systole, is augmented as a com-
pensatory mechanism.52,53
Systolic dysfunction becomes evident in cirrhotics,
during exercise or stress. In fact, under these conditions,
ejection fraction, CO and HR do not rise as expected.
This could explain the possible occurrence of acute
pulmonary oedema and congestive heart failure following
stressing procedures that suddenly increase blood flow to
the heart chambers. A pharmacological (dobutamine)
stress test can unmask a latent cardiac dysfunction in
cirrhotic patients.54 Latent cardiac dysfunction was
defined as a decrease of less than 10% in left ventricular
end-diastolic volume, a decrease of less than 20% in end-
systolic volume and an increase of less than 10% in LVEF
at peak dobutamine infusion (40mg/kg/min). Donovan
et al.55 reported that a preoperative dobutamine stress
echocardiography revealed ischemia in 11 out of 165
patients (7%), five of whom had resting wall motion
abnormalities, while 148 patients (89%) had normal rest-
ing studies and no ischemia with dobutamine. A negative
dobutamine stress echocardiogram was useful in exclud-
ing patients at risk for perioperative cardiac events
related to obstructive CAD.55
Diastolic dysfunction is proper of cirrhotic cardiomyo-
pathy as it has been documented by several studies.56,57
The most frequent diastolic alteration is first-degree
diastolic dysfunction, characterized by reduced early
diastolic ventricular filling and increased atrial filling
(E/A <1), prolonged isovolumic relaxation time (IVRT
>80ms) and deceleration time (>200ms), which
represent increased resistance to ventricular inflow
(Fig. 2). The presence of enlarged left atrium (volume
>34ml/mq) is not a diagnostic criterion per se, but rather a
supportive one, due to the presence of volume overload
in cirrhotic patients.58 Many studies documented left
atrium enlargement in cirrhotic cardiomyopathy, as well
as mild dilatation of end-diastolic and end-systolic left
ventricle volumes.59
A key element to diagnose diastolic dysfunction is the
measurement of a reduced E’ velocity, at the site of mitral
annulus, by Tissue Doppler (septal <8 cm/s, lateral
<10 cm/s)60 (see Fig. 2). Diastolic filling pressure may
be esteemed by the E/E’ ratio (E wave measured by
pulsed Doppler of mitral inflow and E’ wave measured
with Tissue Doppler at the site of mitral annulus).60
Kazankov et al.51 reported substantial diastolic myocardialthorized reproduction of this article is prohibited.
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Fig. 2
Echocardiographic study. Transmitral flow pattern (upper panel) showing E/A ratio <1 and Tissue Doppler recorded at the site of mitral annulus
(lower panel) showing reduction of E’ and S wave (<8 cm/s), in a patient with cirrhotic cardiomyopathy.dysfunction during rest, by Tissue Doppler imaging, in
cirrhotic patients. Woo et al.61 reported increased E/E’
ratio in cirrhotic patients. The pathophysiological back-
ground of the diastolic dysfunction in cirrhosis is an
increased stiffness of the myocardial wall, most likely
caused by histological alteration such as mild myocardial
hypertrophy, fibrosis and subendothelial oedema.62
There is experimental as well as clinical evidence that
increased sodium retention can modulate cardiac mass,opyright © 2015 Wolters Kluwer Health, Inc. Unaleading mainly to concentric hypertrophy; however, the
mechanism by which it occurs is not clear, probably
interfering with cardiac sympathetic activity and renin
angiotensin system (RAS).63,64 Sodium induces changes
in cardiac norepinephrine and receptor characteristics,
thus leading to the hypothesis that it can influence
cardiac sympathetic activity. However, in experimental
studies, the lack of an increase in left ventricular norepi-
nephrine turnover and tyrosine hydroxylase activity
suggests that the hypertrophy is not mediated throughuthorized reproduction of this article is prohibited.
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Table 1 Diagnostic features of cirrhotic cardiomyopathy
Echocardiography Systolic function:
Nearly normal EF
#PEP; "LVET; #PEP/LVET
Tissue Doppler: # S wave
Diastolic function:
#E/A (<1)
"IVRT (>80 ms), " DT (>200 ms)
(rarely possible higher degree of diastolic dysfunction)
"E/E’
2D: LA enlargement
Possible: " wall thickness
and mild LV dilation
Stress echo: little increase of CO, and EF
ECG Prolonged QTc
fragmentation of QRS
CMR LGE patchy distribution
Biomarkers " BNP and NT-proBNP
Possible " cTNI
", Increased; #, Reduction; BNP, brain natriuretic peptide; CO, cardiac output;
cTNI, cardiac troponin; DT, deceleration time; EF, ejection fraction; IVRT, iso-
volumic relaxation time; LA, left atrium; LV, left ventricle; LVET, left ventricular
ejection time; PEP, pre-ejection period.increased cardiac neuronal sympathetic activity.63 The
mechanical stretch due to volume overload activates the
intracardiac RAS and this can trigger the intracardiac
production of angiotensin II (Ang II).65 Binding of Ang
II to its angiotensin type1 (AT1) receptors, in the myo-
cardium, activates a cascade of intracellular events pro-
moting cardiomyocytes hypertrophy, via the protein
kinase cascade and extracellular matrix production.66
Moreover, growth hormones for cardiomyocytes, such
as endothelin and norepinephrine, which are hugely
present, especially in decompensated cirrhosis, can cause
cardiac hypertrophy even in the absence of stretch.67,68 A
recent study assessing the role of NF-kB in mediating
systolic dysfunction in cirrhosis also showed an improve-
ment of diastolic relaxation in cardiomyocytes when its
inhibitors blocked NF-kB activity, with a reduction in
TNF-a expression.69 This suggests that an inflammatory
micro-environment could be partly responsible for the
diastolic dysfunction in cirrhosis, but the exact mechan-
ism with which TNF-a affects diastolic dysfunction has
not been yet elucidated. However, Merli et al.70 did not
identify an association between severity of liver disease
and cardiac dysfunction. On the other side, individuals
with a thicker ventricle and more severe diastolic dys-
function were more likely to have heart failure after liver
transplantation.57 Diastolic function tends to return to
normal 6–12 months after a liver transplant.71,72 Table 1
summarizes the main echocardiographic abnormalities in
cirrhotic cardiomyopathy.
Electrical abnormalities
Electrocardiographic abnormalities may represent an
early manifestation of cardiac involvement in patients
with liver cirrhosis. Many studies report an impairment of
electric ventricular recovery, which can be easily revealed
by measuring QT interval. The QT interval prolongation
is traditionally considered a marker of arrhythmic risk inpyright © 2015 Wolters Kluwer Health, Inc. Unauthe general population.73–75 Although QT interval pro-
longation is the most frequent ECG abnormality in the
cirrhotic heart, life-threatening arrhythmias are generally
uncommon.12 Patient with cirrhotic cardiomyopathy may
have a prolonged QTc (QT corrected for HR); the
magnitude of QT interval prolongation could be related
to the severity of liver disease.12,76 Nowadays, the pro-
longation of QT interval is one of the diagnostic criteria of
cirrhotic cardiomyopathy. Figure 3 shows an ECG with
QTc lengthening in a patient with cirrhosis.
Several pathogenic mechanisms are responsible for the
ventricular recovery impairment observed in cirrhotic
patients, such as electrolyte imbalance or changes in
sympathetic activity. Altered cardiomyocyte membrane
fluidity, increased myocardial fibrosis, cardiomyocyte
hypertrophy and ion channel defects are also responsible
for the ventricular recovery impairment. In this regard,
some authors reported alterations of conductance proper-
ties of Kþ and Caþþ channels and abnormalities of ionic
currents in various cells in experimental and human
cirrhosis.77–79 Moreover, various toxins that are elevated
in cirrhosis can contribute to ion channel disturbance,
widening of the QRS complex and consequently prolong-
ing QT intervals.6,12 Some authors80,81 evaluated the
influence of vasoactive peptides on prolonged QT inter-
val. They reported that the prolonged QT is related to
liver dysfunction and presence of portal hypertension,
but not to the amount of vasoconstrictor (ET-1) or
vasodilator (CGRP, ET-3) circulating peptides. How-
ever, the QT interval has been found prolonged after
TIPS insertion, which means that porto-systemic shunt-
ing may play a role in its determinism.82 QT prolongation
is present either in alcoholic or nonalcoholic cirrhosis.
The impact of the specific cirrhosis cause in the genesis of
ventricular repolarization alterations is controversial. In
the study of Bernardi et al.,83 the prevalence of QT
interval prolongation did not differ between patients with
alcohol-related cirrhosis and those with the postviral liver
disease. By contrast, Bal and Thuluvath76 reported that
the prolonged QTc was a more common finding in
patients with alcoholic cirrhosis (60%) than in nonalco-
holic ones (35%), and that alcoholic cirrhosis was an
independent predictor of QT interval prolongation.
Other studies emphasize the role of drugs potentially
linked to QT interval lengthening, showing a higher risk
of sudden cardiac death in individuals with cirrhosis
during treatment with drugs, such as neuroleptics.84More
recently, Genovesi et al.82 carried out a study aiming to
assess the determinants of QT interval prolongation in
cirrhotic patients, evaluating the 24-h mean QTc inter-
vals, the slope of the regression line QT/RR, HR varia-
bility (HRVHR variability), plasma calcium and
potassium concentration and hepatic venous pressure
gradient (HVPG). They showed that there was a signifi-
cant correlation between QTc and hepatic venous pres-
sure gradient. Further, they also showed that patientsthorized reproduction of this article is prohibited.
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Fig. 3
ECG and cardiac magnetic resonance. Upper panel: ECG showing mild QTc lengthening (447 ms). Lower panel: CMR study showing a case of
LGE patchy distribution.with alcohol-related cirrhosis presented QTc pro-
longation more frequently than those with postviral cir-
rhosis and that the plasma calcium concentration was
inversely correlated with QTc. Furthermore, the pre-
sence of severe portal hypertension was associated withopyright © 2015 Wolters Kluwer Health, Inc. Unadecreased HRV. Thus, it is possible to conclude that
cirrhotic patients with a more severe disease, especially of
alcoholic cause, who have greater HVPG and lower
calcium plasma levels, are more likely to have abnorm-
alities of ventricular repolarization.uthorized reproduction of this article is prohibited.
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dispersion (QTdisp), defined as the interlead QT varia-
bility, in 23 patients with cirrhosis; they also evaluated a
possible relationship between ECG markers and haemo-
dynamic changes. They reported that mean QT(c) was
above upper normal limit in 47% of cirrhotic patients, and
that the minimum value of QT(c) (but not the maximum
value) showed a significant diurnal variation and that
QT(disp) was significantly related to indicators of liver
dysfunction, central circulation time and arterial blood
pressure. These findings could suggest that a combi-
nation of long QT(c) and normal QT(disp) may indicate
delayed myocyte repolarization at the cellular level,
rather than temporal and spatial heterogeneity in the
myocardial wall.
Another possible issue to consider among the electrical
abnormalities of cirrhotic cardiomyopathy is the evalu-
ation of fragmentation of QRS (fQRS) complex, which is
an easily accessible, noninvasive electrocardiographic
parameter. Fragmentation of narrow QRS is defined as
the presence of an additional R wave (R’) or notching in
the nadir of the S wave, or the presence of more than 1 R’
in two contiguous leads.86 The presence of fQRS has
been associated with alternation of myocardial activation
due to myocardial scar and myocardial fibrosis. Initial
studies reported a higher sensitivity of fQRS than Qwave
for detecting myocardial scar. Furthermore, they postu-
lated that the presence of fQRS could be a good predictor
of cardiac events among different types of patients,
indicating its capability to evaluate electrocardiographic
abnormalities of cirrhotic patients with cirrhotic cardio-
myopathy. The main electrocardiographic abnormalities
of cirrhotic cardiomyopathy are summarized in Table 1.
Cardiovascular nuclear MRI
Cardiovascular magnetic resonance (CMR) has become
the gold standard method for the assessment of cardiac
morphology and function in various cardiomyopathies
(CMPs).87 Areas of high signal intensity appearing 10–
15min after injection of the intercellular contrast agent
gadolinium were firstly described as late gadolinium
enhancement (LGE) in regions of myocardial scarring
after infarction.88 Afterwards, it was shown that LGE
could also be detected in nonischemic CMP, cardiac
neoplasm, myocarditis, cardiomyopathy and storage dis-
eases such as amyloidosis.89 Typical LGE patterns have
been defined for each of these diseases allowing differ-
ential diagnosis and etiological allocation.90–92 Moreover,
the presence and the extent of LGE was shown to be a
prognostic indicator.93
CMR has been used for the evaluation of functional
myocardial changes, noninvasive tissue characterization
and the identification of specific cardiac lesions in cir-
rhotic patients listed for liver transplantation.94,95 CMR
and particularly the presence of LGE seems to be a
promising tool to identify patients with end-stage liverpyright © 2015 Wolters Kluwer Health, Inc. Unaudisease at risk for cirrhotic cardiomyopathy. LGE can be
detected regardless of the cause of liver disease, even if it
is more pronounced in patients with alcoholic liver cir-
rhosis. LGE pattern in cirrhotic cardiomyopathy differs
from other nonischemic CMP or myocardial infarction
and shows a patchy distribution comparable to that found
in acute myocarditis96,97 (see Fig. 3).
LGE can be due to other causes beyond fibrosis, such as
pathological deposits, causing local myocardial injury
(e.g. cardiotoxic metabolites, oxygen supply/demand
mismatch due to pulmonary arteriovenous shunts, inflam-
mation); this can explain the focal, rather than diffuse,
distribution of LGE found in cirrhotic patients. Accord-
ingly, previous studies showed that cardiomyocytes and
the trabecular network of the myocardium are changed in
cirrhotic patients.97 Inflammatory process and hyperdy-
namic circulation in portal hypertension may also play a
role in the detection of LGE. Cardiac complications are a
frequent cause of morbidity and mortality in patients
undergoing liver transplantation and TIPS. Rates of
pulmonary oedema have been reported to occur in up
to 56% of liver transplant recipients following surgery,
and haemodynamically significant arrhythmias in 27%,
and congestive heart failure in as many as 5.6%.98 In a
more recent study, 82 out of 179 patients after liver
transplantation suffered from cardiac decompensation
and cardiac causes were the leading cause of death in
these patients.99 Liver transplant and TIPS pose a stress
on the cardiocirculatory system and can lead to a decom-
pensation of cardiac function. This occurs despite regular
and careful previous cardiological evaluation.100 For this
reason, CMR could represent a useful tool, although
expensive, for investigating patients before undergoing
liver transplantation and TIPS.101
As previous studies demonstrated a normalization of the
haemodynamic parameters after liver transplantation in
end-stage liver disease patients,55,101 further studies are
needed, investigating the extent of a possible reversibil-
ity of these myocardial alterations.
Cardiac biomarkers
Troponin I, a thin filament associated protein of the
myocytes cytoskeleton, is a specific and sensible marker
of cardiac injury. It remarkably increases in patients with
even very small myocardial infarction, but it is not
specific of an ischemic cause. Therefore, it is also released
when cellular death occurs for other reasons as well as in
patients with cirrhosis.102 atrial natriuretic peptide and B-
type natriuretic peptide (BNP) are secreted from the
cardiac atria and ventricles in response to increased
cardiac preload. BNP and its pro-hormone, NT pro-
BNP, are sensitive markers of myocardial injury. They
have been found to be increased in both compensated
and decompensated cirrhosis. In a recent study, we have
shown that NT pro-BNP plasma levels are raised pro-
portionally to the stage of chronic liver disease and arethorized reproduction of this article is prohibited.
CCE: Tripti; JCM-D-14-00618; Total nos of Pages: 11;
JCM-D-14-00618
Cardiac involvement in cirrhosis Licata et al. 9significantly associated with increased left atrial volumes
and with signs of cardiac diastolic dysfunction.103 Overall,
these peptides seem to correlate with the severity of
cirrhosis (Child–Pugh score, HVPG and serum albumin),
degree of cardiac dysfunction (plasma volume, HR and
QT interval) and myocardial hypertrophy, but not with
the degree of hyperdynamic circulation.104,105 AS BNP
and NT pro-BNP reflect the presence of myocardial
hypertrophy and cardiac dysfunction in compensated
cirrhosis, their evaluation may be useful in screening
patients for the presence of cirrhotic cardiomyopathy.106
Therapeutic perspectives and prognostic
implications
There is no specific therapy for patients with cirrhotic
cardiomyopathy and they are usually asymptomatic unless
undergoing stressful procedures. When symptoms
develop, therapy is mainly aimed to treat heart failure.
To reduce congestion, therapy with diuretics can be
administered, including aldosterone antagonists, which
can favour hypertrophy regression and improvement of
diastolic function.26 Vasodilators, such angiotensin-con-
verting enzyme (ACE)-inhibitors should be used with
caution, because they could aggravate the state of systemic
vasodilation. Beta-blockers, which find an indication for
reducing portal hypertension, can be also useful to reduce
QT interval. Liver transplantation usually leads to
regression of cardiac dysfunction.6–12
Conclusion
Cirrhotic cardiomyopathy is a relatively recent recog-
nized condition. It is characterized by normal systolic
function and mild diastolic dysfunction at rest, and
inability to increase CO under stressful conditions such
as TIPS insertion or liver transplantation, in the absence
of known cardiac disease and irrespective of cirrhosis
cause. Although recently the awareness of the syndrome
increased, the real dimension of the problem remains
unclear, because patients are asymptomatic at rest and
they are usually diagnosed during end-stage liver disease.
However, nowadays, it is not easy to understand the
amount of cardiac dysfunction really attributable to cir-
rhosis, due to the frequent coexistence of confounding
conditions and/or comorbidities, such as smoking, hyper-
tension, diabetes, CAD. Comorbidities of cirrhosis some-
times could antedate the onset of chronic liver disease,
irrespective of cause, but influencing its pathophysiology.
More studies are needed to better investigate the under-
lying pathogenetic mechanisms of cardiac dysfunction in
patients with cirrhosis and to improve diagnostic work-up
and risk stratification.
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